Галерея
Всего фотографий: 1.081
Всего просмотров: 2072418
Всего просмотров: 2072418
13
1369
1370
1371
1368
1367
1366
1365
1364
1363
1362
1361
1360
1359
1358
1357
1356
1355
1354
1353
1352
1351
1350
1349
1348
1347
1346
1345
1344
1343
1342
1341
1340
1339
1338
1337
1336
1335
1334
1333
1332
1331
1330
1329
1328
1327
1326
1325
1324
1323
1322
1318
1317
1316
1315
1314
1313
1312
1311
1310
1309
1308
1307
1306
1305
1304
1303
1302
1285
1283
1284
1280
1279
1278
1277
1272
1271
1270
1262
1261
1260
1259
1255
1254
1253
1252
1251
1250
1249
1248
1247
1246
1245
1244
1243
1242
1241
1240
1239
1238
1233
1232
1231
1230
1229
1218
1217
1216
1215
1214
1213
1212
1211
1210
1209
1208
1204
1203
1202
1194
1193
1192
1191
1190
1189
1188
1187
1186
1185
1184
1183
1182
1181
1180
1174
1173
1172
1171
1175
1176
1170
1169
1168
1161
1160
1154
1153
1152
1151
1150
1135
1134
1133
1132
1108
1107
1106
1105
979
978
977
962
961
960
356
250
249
248
247
246
245
244
1269
Информация о фото
Описание:
Дата:
30.07.2025 08:50:07
Число просмотров:
181
Оценка:
Нет
Размер файла:
109,93 KB (400 x 300 px)
Размер оригинального файла:
439,40 KB (2000 x 1500 px)
Оценка фотографии
Всего фотографий: 1.081
Всего просмотров: 2072418
Всего просмотров: 2072418
Комментарии к фото
Tesamorelin is a synthetic peptide that mimics growth hormone releasing hormone
(GHRH) and stimulates the pituitary gland to produce more growth hormone.
By boosting endogenous growth hormone levels, it can promote lipolysis
in abdominal fat, improve insulin sensitivity, and alter body composition. The drug has been approved for reducing excess visceral adipose tissue in patients with HIV-associated lipodystrophy,
but its potential uses extend beyond this indication. Like any pharmacologic agent,
tesamorelin carries a risk of adverse effects
that vary in frequency and severity.
Understanding Tesamorelin: Mechanism, Results, and Potential [url=https://www.valley.md/understanding- -ipamorelin-side-effects]gh-related side effects[/url] Effects
Mechanism of Action
Tesamorelin binds to the GHRH receptors on somatotrophs in the anterior pituitary.
This interaction activates adenylate cyclase, increasing cyclic AMP production and leading to the release of
growth hormone into circulation. The elevated growth hormone subsequently stimulates hepatic secretion of insulin-like growth factor 1 (IGF‑1), which mediates many anabolic effects such as protein synthesis, lipolysis, and glucose uptake.
Clinical Outcomes
In randomized controlled trials involving HIV-positive adults with excess
abdominal fat, daily subcutaneous injections of tesamorelin at a dose of 2 mg reduced visceral adipose tissue
by approximately 20–25% over six months. Secondary benefits included modest improvements in fasting
insulin levels, lipid profiles, and markers of inflammation. In other studies, tesamorelin has been shown to increase lean body
mass and improve muscle strength in older adults with sarcopenia, although larger trials are needed for definitive conclusions.
Common Side Effects
The most frequently reported adverse events arise from the anabolic actions of growth hormone and include local injection site reactions such
as pain, erythema, or swelling. Systemic effects encompass edema, joint discomfort,
and muscle aches, reflecting fluid retention and increased protein turnover.
Some patients experience transient headaches or fatigue.
Because tesamorelin elevates IGF‑1 levels, there is a theoretical
risk of glucose intolerance; however, most trials have shown neutral or modestly beneficial effects on glycemic control.
Less Common but Serious Risks
Rare but notable complications involve the development
of insulin resistance, especially in individuals with pre-existing
metabolic disorders. There is also concern for growth hormone–associated neoplasia, although no definitive causal link has been established in humans.
Patients with a history of untreated thyroid disease may
experience exacerbated symptoms due to the stimulatory effects on peripheral conversion of T4 to T3.
Rare allergic reactions have been documented, presenting as urticaria or anaphylaxis.
Long-Term Safety Profile
Because tesamorelin is not approved for long-term use outside of specific indications, data beyond 12–24 months are limited.
Ongoing surveillance has reported no significant increase in cancer incidence compared with placebo, but vigilance remains essential.
Regular monitoring of IGF‑1 levels and metabolic parameters is recommended to detect potential adverse trends early.
Tesamorelin: A Simple Guide
Indications
The only FDA-approved indication is the reduction of excess abdominal fat
in HIV-positive adults with lipodystrophy. Off-label use for body composition improvement, muscle
wasting, or anti-aging purposes is reported but lacks
robust evidence.
Dosage and Administration
Standard dosing involves a daily subcutaneous
injection of 2 mg administered at the same time each
day to maintain steady-state levels. The drug should be mixed with a sterile diluent before injection, and the site should be rotated to minimize local reactions.
Monitoring Recommendations
Patients should undergo baseline fasting glucose, lipid panel, thyroid function tests, and IGF‑1 measurement.
Follow-up labs are typically performed at 4–6 weeks after initiation and then quarterly.
Clinicians should assess for signs of fluid retention, joint
pain, or new-onset insulin resistance.
Contraindications and Precautions
Tesamorelin is contraindicated in patients with active malignancy or uncontrolled thyroid disease.
It may be used cautiously in patients with a history of cancer only under specialist supervision. Caution is
advised when prescribing to individuals with severe renal impairment, as clearance data are sparse.
Lifestyle Considerations
Exercise and dietary modifications should accompany therapy to maximize
visceral fat loss and prevent compensatory weight gain. Patients should avoid excessive alcohol
intake, which can exacerbate liver dysfunction or interfere with hormone metabolism.
Patient Education Points
Explain that while tesamorelin can improve body composition, it is not a cure for HIV-associated metabolic complications.
Discuss the importance of adherence to injection schedules and reporting any new symptoms promptly.
Emphasize the need for routine laboratory monitoring
to safeguard against potential adverse effects such
as hyperglycemia or elevated IGF‑1.
In summary, tesamorelin offers targeted benefits in reducing visceral adiposity
through growth hormone stimulation but carries a spectrum of side effects
ranging from mild injection site discomfort to more serious metabolic
disturbances. A balanced approach that includes careful patient selection, regular monitoring,
and supportive lifestyle measures can help mitigate risks while
maximizing therapeutic gains.